CADL Candel Therapeutics Forecast, Technical & Fundamental Analysis
Candel Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing off-the-shelf viral immunotherapies that elicit an individualized, systemic anti-tumor immune response to help patients fight cancer... Show more
CADL is expected to report earnings to rise 73.71% to -24 cents per share on August 19
Q2'26
Est.
$-0.24
Q1'26
Beat
by $0.20
Q4'25
Missed
by $0.29
Q3'25
Missed
by $0.03
Q2'25
Beat
by $0.07
The last earnings report on May 14 showed earnings per share of -14 cents, beating the estimate of -34 cents. With 1.05M shares outstanding, the current market capitalization sits at 617.67M.
A.I.dvisor indicates that over the last year, CADL has been loosely correlated with AURA. These tickers have moved in lockstep 47% of the time. This A.I.-generated data suggests there is some statistical probability that if CADL jumps, then AURA could also see price increases.
CADL sees its 50-day moving average cross bullishly above its 200-day moving average
The 50-day moving average for CADL moved above the 200-day moving average on May 08, 2026. This could be a long-term bullish signal for the stock as the stock shifts to an upward trend.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on June 02, 2026. You may want to consider a long position or call options on CADL as a result. In of 97 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where CADL advanced for three days, in of 237 cases, the price rose further within the following month. The odds of a continued upward trend are .
The Aroon Indicator entered an Uptrend today. In of 91 cases where CADL Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .
Bearish Trend Analysis
The 10-day RSI Indicator for CADL moved out of overbought territory on May 18, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 27 similar instances where the indicator moved out of overbought territory. In of the 27 cases, the stock moved lower in the following days. This puts the odds of a move lower at .
The Stochastic Oscillator entered the overbought zone. Expect a price pull-back in the foreseeable future.
The Moving Average Convergence Divergence Histogram (MACD) for CADL turned negative on May 19, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 43 similar instances when the indicator turned negative. In of the 43 cases the stock turned lower in the days that followed. This puts the odds of success at .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CADL declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
CADL broke above its upper Bollinger Band on May 11, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. CADL’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to slightly better than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.474) is normal, around the industry mean (21.430). P/E Ratio (0.000) is within average values for comparable stocks, (35.359). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.649). CADL has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.039). P/S Ratio (0.000) is also within normal values, averaging (362.782).
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CADL’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
